Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/162065
Title: Tumor-microenvironment-activatable polymer nano-immunomodulator for precision cancer photoimmunotherapy
Authors: Liu, Jing
He, Shasha
Luo, Yingli
Zhang, Yue
Du, Xiaojiao
Xu, Cheng
Pu, Kanyi
Wang, Jun
Keywords: Engineering::Bioengineering
Issue Date: 2022
Source: Liu, J., He, S., Luo, Y., Zhang, Y., Du, X., Xu, C., Pu, K. & Wang, J. (2022). Tumor-microenvironment-activatable polymer nano-immunomodulator for precision cancer photoimmunotherapy. Advanced Materials, 34(8), e2106654-. https://dx.doi.org/10.1002/adma.202106654
Project: 2019-T1-002-045 
RG125/19 
MOE2018-T2-2-042 
SERC A18A8b0059
Journal: Advanced Materials
Abstract: Cancer nanomedicine combined with immunotherapy has become a promising strategy for treating cancer in terms of safety and potency; however, precise regulation of the activation of antitumor immunity remains challenging. Herein, a smart semiconducting polymer nano-immunomodulator (SPNI), which responds to the acidic tumor microenvironment (TME), for precision photodynamic immunotherapy of cancer, is reported. The SPNI is self-assembled by a near-infrared (NIR)-absorbing semiconducting polymer and an amphipathic polymer conjugated with a Toll-like receptor 7 (TLR7) agonist via an acid-labile linker. Upon arrival at tumor site, SPNI undergoes hydrolysis and triggers an efficient liberation of TLR7 agonist in response to the acidic TME for dendritic cell activation. Moreover, SPNI exerts photodynamic effects for direct tumor eradication and immunogenic cancer cell death under NIR photoirradiation. The synergistic action of released immunogenic factors and acidic-TME-activated TLR7 agonist can serve as an in situ generated cancer vaccine to evoke strong antitumor activities. Notably, such localized immune activation boosts systemic antitumor immune responses, resulting in enhanced cytotoxic CD8+ T infiltration to inhibit tumor growth and metastasis. Thereby, this work presents a general strategy to devise prodrug of immunotherapeutics for precise regulation of cancer immunotherapy.
URI: https://hdl.handle.net/10356/162065
ISSN: 0935-9648
DOI: 10.1002/adma.202106654
Rights: © 2022 Wiley-VCH GmbH. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:SCBE Journal Articles

SCOPUSTM   
Citations 20

12
Updated on Nov 26, 2022

Web of ScienceTM
Citations 20

11
Updated on Nov 25, 2022

Page view(s)

18
Updated on Nov 29, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.